Vaxcyte Inc - Asset Resilience Ratio
Vaxcyte Inc (PCVX) has an Asset Resilience Ratio of 41.54% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Vaxcyte Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Vaxcyte Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vaxcyte Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Vaxcyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore PCVX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.30 Billion | 41.54% |
| Total Liquid Assets | $1.30 Billion | 41.54% |
Asset Resilience Insights
- Very High Liquidity: Vaxcyte Inc maintains exceptional liquid asset reserves at 41.54% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vaxcyte Inc Industry Peers by Asset Resilience Ratio
Compare Vaxcyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Vaxcyte Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Vaxcyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 45.54% | $1.39 Billion | $3.05 Billion | +6.82pp |
| 2024-12-31 | 38.71% | $1.36 Billion | $3.51 Billion | -9.78pp |
| 2023-12-31 | 48.50% | $682.78 Million | $1.41 Billion | +38.88pp |
| 2022-12-31 | 9.61% | $96.72 Million | $1.01 Billion | -44.96pp |
| 2021-12-31 | 54.57% | $176.99 Million | $324.34 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $392.83 Million | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more